PatientsVille.com Logo


Triglide Medical Research Studies

Up-to-date List of Triglide Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Triglide Medical Research Studies

Rank Status Study
1 Recruiting Phase 2 Fenofibrate in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Fenofibrate
Outcome Measures: Number of Patients Achieving Response to Fenofibrate Therapy;   Number of Subjects Experiencing Adverse Events;   Number of Subjects Achieving Progression-Free Survival
2 Recruiting Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient(CKD-337)
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 20mg;   Drug: Fenofibrate 160mg;   Other: Placebo (Fenofibrate 160 mg)
Outcome Measures: The mean percent change of Non-HDL Cholesterol;   The achievement rate of LDL-C<100mg/dl, Non-HDL-C<130mg/dl;   The mean percent change of LDL-C, HDL-C, TG, TC, Apo-AI, Apo-B;   The mean percent change of Non-LDL-C/HDL-C, TC/HDL-C, LDL-C/HDL-C, Apo-B/Apo-AI;   The mean percent change of Fibrinogen, hs-CRP
3 Not yet recruiting A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume
Conditions: Type 1 Diabetes Mellitus;   Retinopathy;   Diabetic Nephropathy
Interventions: Drug: Fenofibrate;   Drug: Inert lactose placebo
Outcome Measures: Central zone macular thickness measured using optical coherence tomography;   Total macular volume measured using optical coherence tomography.;   Albuminuria measured as urinary albumin:creatinine ratio.;   Visual acuity using Snellen Chart;   Corneal confocal microscopic measurement of neural damage (only assessed in a representative subset of the participants at sites with the specialised confocal microscope).;   Estimated glomerular filtration rate using MDRD formula;   Peripheral neuropathy status assessed by temperature sensation and monofilament sensation.;   Vascular function using non-invasive pulse wave techniques and plethysmography.;   Blood lipids and biomarkers in plasma
4 Recruiting Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients
Condition: Second or Third Degree Burns
Interventions: Drug: Fenofibrate;   Drug: placebo
Outcome Measures: Mitochondrial fatty acid oxygenation;   Insulin sensitivity;   Protein Metabolism;   Glucose Metabolism;   Amino Acid Metabolism
5 Recruiting Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Diabetes Mellitus, Type 2;   Hypertriglyceridemia
Interventions: Drug: Fenofibrate;   Drug: Simvastatin
Outcome Measures: Percentage change from baseline in triglycerides (TG) at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12;   Percentage changes from baseline in apoB/apoA1 ratio at week 12;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12;   Percentage changes from baseline in uric acid at week 12;   Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52;   Percentage changes from baseline in apoB/apoA1 ratio at week 52;   Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52;   Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52;   Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52;   Percentage changes from baseline in uric acid at week 52
6 Recruiting Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate
Condition: Hypertriglyceridemia
Interventions: Drug: placebo;   Drug: fenofibrate/omega;   Drug: fenofibrate
Outcome Measures: flow-mediated dilation;   insulin resistance
7 Recruiting Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin
Condition: Healthy Male Volunteers
Interventions: Drug: micronized fenofibrate 160mg;   Drug: pitavastatin Ca 2mg;   Drug: micronized fenofibrate 160mg plus pitavastatin Ca 2mg
Outcome Measures: Drug-Drug interaction evaluation (Cmax,ss, Cmin,ss, Tmax,ss);   Number of participants with adverse events
8 Unknown  Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia
Condition: Dyslipidemia
Interventions: Drug: High-dose rosuvastatin;   Drug: Statin plus fenofibrate;   Drug: Statin plus niacin ER/laropiprant
Outcome Measure: Changes in non-HDL-C levels
9 Recruiting Effects of Fenofibrate on Endothelial Progenitor Cells in Type 1 Diabetes
Conditions: Type 1 Diabetes;   Diabetic Retinopathy
Interventions: Drug: Fenofibrate 145 mg;   Drug: Placebo
Outcome Measures: Endothelial progenitor cells;   Oxidized LDL
10 Unknown  Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
Interventions: Drug: Fenofibrate;   Other: Placebo
Outcome Measures: Hepatic adiposity as assessed using MRI;   Body composition using bioelectrical impedance analysis (BIA), anthropometry (skin-fold thickness measurement), and MRI;   Insulin resistance using HOMA-IR;   Biochemical parameters related to insulin resistance (adipocytokines, free fatty acids, 25-hydroxyvitamin D);   Traditional and non-traditional cardiovascular risk factors (lipids, apolipoproteins, fibrinogen, PAI-1, CRP);   Reproductive parameters (androgens, hirsutism)
11 Available A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome
Conditions: Diabetes;   CVD
Intervention: Drug: Rosuvastatin,SFC fenofibrate
Outcome Measure:
12 Unknown  Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
Conditions: HIV;   Hyperlipidemia;   HIV Infections
Interventions: Drug: ezetimibe;   Drug: fenofibrate;   Drug: pravastatin
Outcome Measure: per cent changes of LDL cholesterol, comparison between the 2 treatment regimens
13 Recruiting Medication Development in Alcoholism: Investigating PPAR Agonists
Condition: Alcoholism
Interventions: Drug: Sugar Pill;   Drug: TRICOR (fenofibrate)
Outcome Measures: Craving to Drink;   Drinking Measured by Timeline Follow Back Interview
14 Recruiting Lipid Biomarkers for Diabetic Heart Disease
Conditions: Type II Diabetes Mellitus;   Diabetes Complications
Interventions: Drug: Fenofibrate;   Drug: Placebo for fenofibrate
Outcome Measure: Change in cardiac function as measured by fractional shortening percent
15 Not yet recruiting CKD-337 Drug Interaction Study
Conditions: Dyslipidemia (Fredrickson Type Ⅱa);   Dyslipidemia (Fredrickson Type Ⅱb)
Interventions: Drug: Fenofibrate;   Drug: Atorvastatin
Outcome Measures: AUCt, Cmax,ss of fenofibric acid and atorvastatin;   Tmax,ss, Cmin,ss, t1/2, CL/Fss, Vd/Fss, %swing, Cav, %fluctuation
16 Unknown  Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Conditions: Insulin Resistance;   Hypertriglyceridemia
Interventions: Drug: Rosiglitazone;   Drug: Fenofibrate;   Behavioral: Weight Loss
Outcome Measures: Compare the effect of these three treatments on CVD risk factors.;   Compare the effect of these three treatments on changes in endothelial function
17 Unknown  Jiangzhuo Prescription ,Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)
Conditions: Metabolic Syndromes;   Hyperlipidemia
Outcome Measure:
18 Not yet recruiting The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines
Conditions: Diabetes;   Dyslipidemia;   Inflammation;   Cytokines
Intervention: Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Outcome Measures: Antiinflammatory effects of combined antidiabetic and hypolipemic treatment;   Insulin sensitivity;   Coagulation parameters
19 Available Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia
Condition: Hyperlipidemia
Interventions: Drug: rosuvastatin,fenofibrate;   Genetic: CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP
Outcome Measure:
20 Recruiting Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
Condition: Metabolic Syndrome
Intervention: Other: Not applicable-observational study
Outcome Measures: The incidence rate of the major adverse cardiovascular events (MACE);   The incidence rate of the major adverse cardiac and cerebrovascular event (MACCE)

These studies may lead to new treatments and are adding insight into Triglide etiology and treatment.

A major focus of Triglide research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Triglide